发明名称 |
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
摘要 |
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain. |
申请公布号 |
US9439900(B2) |
申请公布日期 |
2016.09.13 |
申请号 |
US201414577823 |
申请日期 |
2014.12.19 |
申请人 |
Orexo AB |
发明人 |
Fischer Andreas |
分类号 |
A61K31/4748;A61K9/14;A61K31/485;A61K9/20;A61K9/00 |
主分类号 |
A61K31/4748 |
代理机构 |
LeClairRyan, a Professional Corporation |
代理人 |
LeClairRyan, a Professional Corporation |
主权项 |
1. A pharmaceutical composition in the form of a tablet suitable for sublingual administration comprising:
buprenorphine, or a pharmaceutically acceptable salt thereof, provided in the form of microparticles, a weak acid, provided in the form of particles, which particles are separate from the microparticles of buprenorphine, or a pharmaceutically acceptable salt thereof, a disintegrant, and naloxone or a pharmaceutically acceptable salt thereof,wherein the per tablet dosage of buprenorphine (calculated as the free base) is 11.4 mg, 8.6 mg, 5.7 mg, 2.9 mg, or 1.4 mg; andwherein the per tablet dosage ratio of buprenorphine:naloxone dose (calculated as free bases) is about 4:1. |
地址 |
Uppsala SE |